Recent developments in immunotherapy of cancers caused by human papillomaviruses,Immunology

当前位置： X-MOL 学术 › Immunology › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Recent developments in immunotherapy of cancers caused by human papillomaviruses
Immunology ( IF 4.9 ) Pub Date : 2020-11-18 , DOI: 10.1111/imm.13285
Elham Fakhr _{1,

2} , Živa Modic ₁ , Angel Cid-Arregui ₁

Affiliation

A subset of oncogenic human papillomaviruses (HPVs) is the main cause of genital cancers, most importantly cervical cancer and an increasing number of head and neck cancers. Despite the availability of prophylactic vaccines against the most prevalent oncogenic HPV types, HPV‐induced malignancies are still a major health and economic burden. Besides conventional treatment with surgery, chemotherapy and radiation, immunotherapy is emerging as an efficient adjuvant option. Here, we review relevant studies and ongoing clinical trials using immune checkpoint inhibitors, therapeutic vaccines, gene editing approaches and adoptive T cell therapies, with special focus on engineered TCR T cells, which are showing encouraging results and could lead to significant improvement in the treatment of HPV+‐infected cancer patients.

中文翻译：

人乳头瘤病毒引起的癌症免疫治疗的最新进展

致癌性人乳头瘤病毒 (HPV) 的一个子集是生殖器癌症的主要原因，最重要的是宫颈癌和越来越多的头颈癌。尽管针对最流行的致癌 HPV 类型有预防性疫苗可用，但 HPV 诱导的恶性肿瘤仍然是主要的健康和经济负担。除了手术、化学疗法和放射疗法的常规治疗外，免疫疗法正在成为一种有效的辅助选择。在这里，我们回顾了使用免疫检查点抑制剂、治疗性疫苗、基因编辑方法和过继 T 细胞疗法的相关研究和正在进行的临床试验，特别关注工程化 TCR T 细胞，它们显示出令人鼓舞的结果，并可能导致治疗的显着改善HPV+ 感染的癌症患者。

更新日期：2020-11-18

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11